Alzheimer’s Disease Panel
Helping Your Research
Easily assess and monitor primary molecular characteristics of Alzheimer’s disease (AD) with standardized genes covering clinically-derived AD-associated modules. Now AD expression studies can be more reproducible and translationally relevant with an efficient workflow that potentially reduces the time to clinic. Reliably assay AD phenotypes and disease progression for mouse model development and human tissue screening.
- 770 genes specific for AD studies
- Comprehensive assessment of 30 AD-associated gene co-expression modules including 23 neurodegeneration pathways and processes
- Reproducible monitoring of AD progression with age
- Functional screening of potential AD therapeutics
- Customizable with up to 55 additional user-defined genes with Panel Plus option
- nCounter workflow is streamlined, user-friendly, and efficient with just 15 minutes total hands-on time
- Human Panel available off the shelf and Mouse Panel available on-demand as a Custom CodeSet
How It Works
The content included in the nCounter AD panels represent a transcriptomic fingerprint of AD-related changes that can be directly compared to studies of mouse models of disease and back to human tissue. These panels allow for:
Pathway Based Module Analysis
Gene Set Analysis
Built-in compatibility for Panel Plus and Protein analysis
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
† Annotations for 23 fundamental pathways and processes were assigned across all genes in the Mouse AD and Human AD panel allowing for an additional view of important aspects of the onset and progression of neurodegenerative disease. Pathways and processes with >60% representative gene content per module are listed above.
‡ <60% representative pathway and process gene content per module.
* Genes selected based on human-mouse gene homology, maximal coverage of AMP-AD modules, top AGORA candidate gene status (agora.ampadportal.org), representation in AMP-AD module eigengenes, and expression in mouse brain.
Differential protein expression in the hippocampi of resilient individuals identified by digital spatial profiling.
Clinical symptoms correlate with underlying neurodegenerative changes in the vast majority of people. However, an intriguing group of individuals demonstrate neuropathologic changes consistent with Alzheimer disease (AD) yet remain cognitively normal (termed “resilient”).
Spatial molecular profiling of a central nervous system low-grade diffusely infiltrative tumour with INI1 deficiency (CNS LGDIT-INI1) featuring a high-grade AT/RT component.
Key points: – diffusely infiltrative low-grade tumour with SMARCB1/INI1-deficiency (CNS LGDIT-INI1) has been proposed as a new entity – we report the first case of a child with a CNS LGDIT-INI1 with a high-grade AT/RT component at the time of initial surgery – methylation profiles of both the low- and the high-grade component yielded high similarity with ATRT-MYC – spatial transcriptome analyses showed upregulation of glioneuronal markers in the low grade component underlining the concept of diffuse infiltrative behaviour of CNS LGDIT-INI1 – high-grade tumour areas displayed increased translational activity and proliferation as well as MYC pathway activation..
Co-activation of Sonic hedgehog and Wnt signaling in murine retinal precursor cells drives ocular lesions with features of intraocular medulloepithelioma.
Intraocular medulloepithelioma (IO-MEPL) is a rare embryonal ocular neoplasm, prevalently occurring in children. IO-MEPLs share histomorphological features with CNS embryonal tumors with multilayered rosettes (ETMRs), referred to as intracranial medulloepitheliomas.